DMN:FRA
Diamyd Medical AB
тВм┬ареж.режремрей
реж.режреж%
(реж.режреж) 1D
рдиреЛрднреЗрдореНрдмрд░ резрео, реиреж:резрел:реиреи GMT+рез · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Mkt. cap
резрей.репрен┬ардХрд░реЛрдб
Avg. vol.
реж.режреж
Volume
реж.режреж
52-wk high
тВм┬арез.реореж
52-wk low
тВм┬ареж.режрел
No. of employees
рекреи
Mkt. cap
резрей.репрен┬ардХрд░реЛрдб
Avg. vol.
реж.режреж
Volume
реж.режреж
52-wk high
тВм┬арез.реореж
52-wk low
тВм┬ареж.режрел
No. of employees
рекреи
News stories
From web sources and news partners
Chattanooga Times Free Press
·
рекрем рдорд┐рдиреЗрдЯ рдкрд╣рд┐рд▓реЗ
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
Yahoo Finance
·
рез рдШрдгреНрдЯрд╛ рдкрд╣рд┐рд▓реЗ
Stock Market: Will S&P 500 Open Up or Down Today?
BigGo Finance
·
реи рдШрдгреНрдЯрд╛ рдкрд╣рд┐рд▓реЗ
UBS Sets S&P 500 Target of 8,200 by End-2027, Implying Roughly 12% Upside, But Cuts Rating to Neutral
FOREX.com
·
рез рдШрдгреНрдЯрд╛ рдкрд╣рд┐рд▓реЗ
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GADтВЖтВЕ, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Ume├е which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employeesрекреи
Foundedрезрепреорек
Headquarters-
SectorHealth Care
Industry-
Websitediamyd.com